Genomic epidemiology analysis of drug-resistant Mycobacterium tuberculosis distributed in Mexico

PLoS One. 2023 Oct 13;18(10):e0292965. doi: 10.1371/journal.pone.0292965. eCollection 2023.

Abstract

Genomics has significantly revolutionized pathogen surveillance, particularly in epidemiological studies, the detection of drug-resistant strains, and disease control. Despite its potential, the representation of Latin American countries in the genomic catalogues of Mycobacterium tuberculosis (Mtb), the bacteria responsible for Tuberculosis (TB), remains limited. In this study, we present a whole genome sequencing (WGS)-based analysis of 85 Mtb clinical strains from 17 Mexican states, providing insights into local adaptations and drug resistance signatures in the region. Our results reveal that the Euro-American lineage (L4) accounts for 94% of our dataset, showing 4.1.2.1 (Haarlem, n = 32), and 4.1.1.3 (X-type, n = 34) sublineages as the most prevalent. We report the presence of the 4.1.1.3 sublineage, which is endemic to Mexico, in six additional locations beyond previous reports. Phenotypic drug resistance tests showed that 34 out of 85 Mtb samples were resistant, exhibiting a variety of resistance profiles to the first-line antibiotics tested. We observed high levels of discrepancy between phenotype and genotype associated with drug resistance in our dataset, including pyrazinamide-monoresistant Mtb strains lacking canonical variants of drug resistance. Expanding the Latin American Mtb genome databases will enhance our understanding of TB epidemiology and potentially provide new avenues for controlling the disease in the region.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Drug Resistance, Multiple, Bacterial / genetics
  • Genomics
  • Genotype
  • Humans
  • Mexico / epidemiology
  • Microbial Sensitivity Tests
  • Mycobacterium tuberculosis* / genetics
  • Tuberculosis* / drug therapy
  • Tuberculosis, Multidrug-Resistant* / microbiology

Substances

  • Antitubercular Agents

Grants and funding

We are also grateful for the financial support provided by several grants, including the Mexican National Council for Science and Technology (CONACYT) - Ciencia de Frontera – 319590 to CLC; postgraduate scholarships to PMMP and AARG from the CONACYT. Additionally, we are thankful to Tecnologico de Monterrey for their Seed Grant to CLC, MDD and AS, which supported genome sequencing. We would also like to acknowledge StrainBiotech for their contribution of laboratory supplies, which greatly facilitated our research.